Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development
Recruiting · NCT06847932 · Interventional (participants receive a specific treatment) · Lead sponsor: National Defense Medical Center, Taiwan
View the official record on ClinicalTrials.gov →Interventions studied
AF-predict AI-ECG alert system guided management
What this trial is about
Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.
Who can take part
Age range
40 Days to 85 Days
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients in the inpatient department or the outpatient department
- Patients need to have at least one electrocardiogram within one year
Exclusion criteria
- Diagnosis of atrial fibrillation/atrial flutter
- History of atrial fibrillation/atrial flutter catheter ablation
- Patients with cardiac implantable electronic devices
- Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm
- History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs
- Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant
Where it is running
1 location listed.
- Tri-Service General Hospital - Taipei, Taiwan